{"id":451917,"date":"2021-03-05T12:03:03","date_gmt":"2021-03-05T17:03:03","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=451917"},"modified":"2021-03-05T12:03:03","modified_gmt":"2021-03-05T17:03:03","slug":"covid-19-medincell-publishes-an-extensive-ivermectin-safety-expert-analysis","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/covid-19-medincell-publishes-an-extensive-ivermectin-safety-expert-analysis\/","title":{"rendered":"Covid-19: MedinCell Publishes an Extensive Ivermectin Safety Expert Analysis"},"content":{"rendered":"<p>        <!--body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>Covid-19: MedinCell Publishes an Extensive Ivermectin Safety Expert Analysis<\/b><\/p>\n<p>MONTPELLIER, France&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nMedinCell (Paris:MEDCL):\n<\/p>\n<p><b>No safety concern is anticipated that would prevent health authorities from assessing the use of Ivermectin against Covid-19 as a new indication<\/b><\/p>\n<p><b>The expert review written by a prominent toxicologist is an assessment of ivermectin medical safety profile <\/b><\/p>\n<p><b>It is based on an extensive analysis of over 350 articles plus clearly identified and accessible web sources<\/b><\/p>\n<p><b>The analysis will be submitted shortly by the author for peer review to an internationally acknowledged journal <\/b><\/p>\n<p><b>MedinCell is making this review available immediately at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.medincell.com%2Fivermectin&amp;esheet=52391619&amp;newsitemid=20210305005438&amp;lan=en-US&amp;anchor=www.medincell.com%2Fivermectin&amp;index=1&amp;md5=8d23d7e942d39f8e87c082d94bf19d64\">www.medincell.com\/ivermectin<\/a><\/b><\/p>\n<p><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvest.medincell.com%2F%23news&amp;esheet=52391619&amp;newsitemid=20210305005438&amp;lan=en-US&amp;anchor=Access+the+complete+press+release&amp;index=2&amp;md5=c7277e7e7192783047169a4037427171\"><b>Access the complete press release<\/b><\/a><\/p>\n<p><b>About MedinCell <\/b><\/p>\n<p>\nMedinCell is a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO<sup>\u00ae<\/sup> technology with active ingredients already known and marketed. Through the controlled and extended release of the active pharmaceutical ingredient, MedinCell makes medical treatments more efficient, particularly thanks to improved compliance, i.e. compliance with medical prescriptions, and to a significant reduction in the quantity of medication required as part of a one-off or chronic treatment. The BEPO<sup>\u00ae<\/sup> technology makes it possible to control and guarantee the regular delivery of a drug at the optimal therapeutic dose for several days, weeks or months starting from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. Based in Montpellier, MedinCell currently employs more than 130 people representing over 25 different nationalities.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210305005438r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210305005438\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210305005438\/en\/<\/a><\/span><\/p>\n<p>\nMedinCell<br \/>\n<br \/><strong>David Heuz\u00e9<span style=\"font-weight:normal\" \/><\/strong><br \/><strong>Communication leader<span style=\"font-weight:normal\" \/><\/strong><br \/><a rel=\"nofollow\" href=\"mailto:david.heuze@medincell.com\">david.heuze@medincell.com<br \/>\n<\/a><br \/>+33 (0)6 83 25 21 86\n<\/p>\n<p>\nNewCap<br \/>\n<br \/><strong>Mathilde Bohin \/ Louis-Victor Delouvrier<br \/>\n<\/strong><br \/><strong>Investor relations<span style=\"font-weight:normal\" \/><\/strong><br \/><a rel=\"nofollow\" href=\"mailto:medincell@newcap.eu\">medincell@newcap.eu<\/a><strong \/><br \/>+33 (0)1 44 71 98 53\n<\/p>\n<p>\nNewCap<br \/>\n<br \/><strong>Nicolas Merigeau<span style=\"font-weight:normal\" \/><\/strong><br \/><strong>Media relations<br \/>\n<\/strong><br \/><a rel=\"nofollow\" href=\"mailto:medincell@newcap.eu\">medincell@newcap.eu<\/a><strong \/><br \/>+33 (0)1 44 71 94 98\n<\/p>\n<p><b>KEYWORDS:<\/b> France Europe<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Infectious Diseases Other Health Health Pharmaceutical<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210305005438\/en\/863438\/3\/MedinCell-Logo-notagline.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Covid-19: MedinCell Publishes an Extensive Ivermectin Safety Expert Analysis MONTPELLIER, France&#8211;(BUSINESS WIRE)&#8211; MedinCell (Paris:MEDCL): No safety concern is anticipated that would prevent health authorities from assessing the use of Ivermectin against Covid-19 as a new indication The expert review written by a prominent toxicologist is an assessment of ivermectin medical safety profile It is based on an extensive analysis of over 350 articles plus clearly identified and accessible web sources The analysis will be submitted shortly by the author for peer review to an internationally acknowledged journal MedinCell is making this review available immediately at www.medincell.com\/ivermectin Access the complete press release About MedinCell MedinCell is a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/covid-19-medincell-publishes-an-extensive-ivermectin-safety-expert-analysis\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Covid-19: MedinCell Publishes an Extensive Ivermectin Safety Expert Analysis&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-451917","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Covid-19: MedinCell Publishes an Extensive Ivermectin Safety Expert Analysis - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/covid-19-medincell-publishes-an-extensive-ivermectin-safety-expert-analysis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Covid-19: MedinCell Publishes an Extensive Ivermectin Safety Expert Analysis - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Covid-19: MedinCell Publishes an Extensive Ivermectin Safety Expert Analysis MONTPELLIER, France&#8211;(BUSINESS WIRE)&#8211; MedinCell (Paris:MEDCL): No safety concern is anticipated that would prevent health authorities from assessing the use of Ivermectin against Covid-19 as a new indication The expert review written by a prominent toxicologist is an assessment of ivermectin medical safety profile It is based on an extensive analysis of over 350 articles plus clearly identified and accessible web sources The analysis will be submitted shortly by the author for peer review to an internationally acknowledged journal MedinCell is making this review available immediately at www.medincell.com\/ivermectin Access the complete press release About MedinCell MedinCell is a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various &hellip; Continue reading &quot;Covid-19: MedinCell Publishes an Extensive Ivermectin Safety Expert Analysis&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/covid-19-medincell-publishes-an-extensive-ivermectin-safety-expert-analysis\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-05T17:03:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210305005438r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/covid-19-medincell-publishes-an-extensive-ivermectin-safety-expert-analysis\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/covid-19-medincell-publishes-an-extensive-ivermectin-safety-expert-analysis\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Covid-19: MedinCell Publishes an Extensive Ivermectin Safety Expert Analysis\",\"datePublished\":\"2021-03-05T17:03:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/covid-19-medincell-publishes-an-extensive-ivermectin-safety-expert-analysis\\\/\"},\"wordCount\":307,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/covid-19-medincell-publishes-an-extensive-ivermectin-safety-expert-analysis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210305005438r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/covid-19-medincell-publishes-an-extensive-ivermectin-safety-expert-analysis\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/covid-19-medincell-publishes-an-extensive-ivermectin-safety-expert-analysis\\\/\",\"name\":\"Covid-19: MedinCell Publishes an Extensive Ivermectin Safety Expert Analysis - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/covid-19-medincell-publishes-an-extensive-ivermectin-safety-expert-analysis\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/covid-19-medincell-publishes-an-extensive-ivermectin-safety-expert-analysis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210305005438r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-03-05T17:03:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/covid-19-medincell-publishes-an-extensive-ivermectin-safety-expert-analysis\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/covid-19-medincell-publishes-an-extensive-ivermectin-safety-expert-analysis\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/covid-19-medincell-publishes-an-extensive-ivermectin-safety-expert-analysis\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210305005438r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210305005438r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/covid-19-medincell-publishes-an-extensive-ivermectin-safety-expert-analysis\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Covid-19: MedinCell Publishes an Extensive Ivermectin Safety Expert Analysis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Covid-19: MedinCell Publishes an Extensive Ivermectin Safety Expert Analysis - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/covid-19-medincell-publishes-an-extensive-ivermectin-safety-expert-analysis\/","og_locale":"en_US","og_type":"article","og_title":"Covid-19: MedinCell Publishes an Extensive Ivermectin Safety Expert Analysis - Market Newsdesk","og_description":"Covid-19: MedinCell Publishes an Extensive Ivermectin Safety Expert Analysis MONTPELLIER, France&#8211;(BUSINESS WIRE)&#8211; MedinCell (Paris:MEDCL): No safety concern is anticipated that would prevent health authorities from assessing the use of Ivermectin against Covid-19 as a new indication The expert review written by a prominent toxicologist is an assessment of ivermectin medical safety profile It is based on an extensive analysis of over 350 articles plus clearly identified and accessible web sources The analysis will be submitted shortly by the author for peer review to an internationally acknowledged journal MedinCell is making this review available immediately at www.medincell.com\/ivermectin Access the complete press release About MedinCell MedinCell is a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various &hellip; Continue reading \"Covid-19: MedinCell Publishes an Extensive Ivermectin Safety Expert Analysis\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/covid-19-medincell-publishes-an-extensive-ivermectin-safety-expert-analysis\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-05T17:03:03+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210305005438r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/covid-19-medincell-publishes-an-extensive-ivermectin-safety-expert-analysis\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/covid-19-medincell-publishes-an-extensive-ivermectin-safety-expert-analysis\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Covid-19: MedinCell Publishes an Extensive Ivermectin Safety Expert Analysis","datePublished":"2021-03-05T17:03:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/covid-19-medincell-publishes-an-extensive-ivermectin-safety-expert-analysis\/"},"wordCount":307,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/covid-19-medincell-publishes-an-extensive-ivermectin-safety-expert-analysis\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210305005438r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/covid-19-medincell-publishes-an-extensive-ivermectin-safety-expert-analysis\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/covid-19-medincell-publishes-an-extensive-ivermectin-safety-expert-analysis\/","name":"Covid-19: MedinCell Publishes an Extensive Ivermectin Safety Expert Analysis - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/covid-19-medincell-publishes-an-extensive-ivermectin-safety-expert-analysis\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/covid-19-medincell-publishes-an-extensive-ivermectin-safety-expert-analysis\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210305005438r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-03-05T17:03:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/covid-19-medincell-publishes-an-extensive-ivermectin-safety-expert-analysis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/covid-19-medincell-publishes-an-extensive-ivermectin-safety-expert-analysis\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/covid-19-medincell-publishes-an-extensive-ivermectin-safety-expert-analysis\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210305005438r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210305005438r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/covid-19-medincell-publishes-an-extensive-ivermectin-safety-expert-analysis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Covid-19: MedinCell Publishes an Extensive Ivermectin Safety Expert Analysis"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/451917","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=451917"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/451917\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=451917"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=451917"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=451917"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}